CAMS Key Laboratory of Synthetic Biology for Drug Innovation, NHC Key Laboratory of Biotechnology for Microbial Drugs and State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Microb Cell Fact. 2024 Apr 16;23(1):113. doi: 10.1186/s12934-024-02387-0.
Isatropolone A and C, produced by Streptomyces sp. CPCC 204095, belong to an unusual class of non-benzenoid aromatic compounds and contain a rare seven-membered ring structure. Isatropolone A exhibits potent activity against Leishmania donovani, comparable to the only oral drug miltefosine. However, its variably low productivity represents a limitation for this lead compound in the future development of new anti-leishmaniasis drugs to meet unmet clinical needs.
Here we first elucidated the regulatory cascade of biosynthesis of isatropolones, which consists of two SARP family regulators, IsaF and IsaJ. Through a series of in vivo and in vitro experiments, IsaF was identified as a pathway-specific activator that orchestrates the transcription of the gene cluster essential for isatropolone biosynthesis. Interestingly, IsaJ was found to only upregulate the expression of the cytochrome P450 monooxygenase IsaS, which is crucial for the yield and proportion of isatropolone A and C. Through targeted gene deletions of isaJ or isaS, we effectively impeded the conversion of isatropolone A to C. Concurrently, the facilitation of isaF overexpression governed by selected promoters, prompted the comprehensive activation of the production of isatropolone A. Furthermore, meticulous optimization of the fermentation parameters was conducted. These strategies culminated in the attainment of an unprecedented maximum yield-980.8 mg/L of isatropolone A-achieved in small-scale solid-state fermentation utilizing the genetically modified strains, thereby establishing the highest reported titer to date.
In Streptomyces sp. CPCC 204095, the production of isatropolone A and C is modulated by the SARP regulators IsaF and IsaJ. IsaF serves as a master pathway-specific regulator for the production of isatropolones. IsaJ, on the other hand, only dictates the transcription of IsaS, the enzyme responsible for the conversion of isatropolone A and C. By engineering the expression of these pivotal genes, we have devised a strategy for genetic modification aimed at the selective and high-yield biosynthesis of isatropolone A. This study not only unveils the unique regulatory mechanisms governing isatropolone biosynthesis for the first time, but also establishes an essential engineering framework for the targeted high-level production of isatropolone A.
伊莎妥隆 A 和 C 是由链霉菌 CPCC 204095 产生的,属于一类非苯并芳烃化合物,含有罕见的七元环结构。伊莎妥隆 A 对杜氏利什曼原虫具有很强的活性,与唯一的口服药物米替福新相当。然而,其产量变化不大,这限制了该先导化合物在未来开发新的抗利什曼病药物以满足未满足的临床需求方面的应用。
在这里,我们首次阐明了伊莎妥隆生物合成的调控级联,该级联由两个 SARP 家族调节剂 IsaF 和 IsaJ 组成。通过一系列体内和体外实验,鉴定出 IsaF 是一种途径特异性激活剂,可协调伊莎妥隆生物合成所必需的基因簇的转录。有趣的是,发现 IsaJ 仅上调细胞色素 P450 单加氧酶 IsaS 的表达,这对于伊莎妥隆 A 和 C 的产量和比例至关重要。通过靶向缺失 isaJ 或 isaS 基因,我们有效地阻止了伊莎妥隆 A 向 C 的转化。同时,通过选择启动子来实现 isaF 过表达,可全面激活伊莎妥隆 A 的产生。此外,还对发酵参数进行了细致的优化。这些策略最终使我们在利用遗传修饰菌株进行小规模固态发酵时达到了前所未有的最高产量-980.8mg/L 的伊莎妥隆 A,这是迄今为止报道的最高产量。
在链霉菌 CPCC 204095 中,伊莎妥隆 A 和 C 的产生受 SARP 调节因子 IsaF 和 IsaJ 调节。 IsaF 是伊莎妥隆产生的主途径特异性调节剂。另一方面,IsaJ 仅调节 IsaS 的转录,IsaS 是伊莎妥隆 A 和 C 转化的酶。通过工程化表达这些关键基因,我们设计了一种遗传修饰策略,旨在选择性和高产生物合成伊莎妥隆 A。本研究不仅首次揭示了伊莎妥隆生物合成的独特调控机制,还为靶向高产伊莎妥隆 A 的生产建立了必要的工程框架。